mychesco.com
FDA Approves TREMFYA® for Crohn's Disease, Offering New Treatment Options
This FDA approval adds another biologic option (an IL-23 inhibitor) for adults with moderate-to-severe Crohn’s disease, including both self-administered subcutaneous dosing and an IV induction route. New options may matter for people who haven’t responded to or tolerated existing therapies.
Adults with moderately to severely active Crohn’s disease, patients who have not responded to other biologics or conventional therapies, clinicians treating IBD, and researchers tracking IBD drug development and comparative effectiveness.
What To Know
FDA approved TREMFYA (guselkumab) for adults with moderately to severely active Crohn’s disease. The article highlights that TREMFYA is an interleukin-23 (IL-23) inhibitor and notes it is the first IL-23 drug for Crohn’s with both subcutaneous (SC) and intravenous (IV) induction options.
Dosing details reported: SC induction 400 mg at Weeks 0, 4, and 8 with maintenance 100 mg every 8 weeks or 200 mg every 4 weeks as needed; an IV induction option is also available.
The approval is said to be supported by Phase 3 trial data (GRAVITI and GALAXI) including >1,300 patients and comparisons versus STELARA were mentioned for key endoscopic endpoints. The article also references a company patient-support program (TREMFYA® withMe) to help access.
This is a regulatory/news announcement summarizing the approval and company comments; it does not provide full trial data or safety details.
If you are considering treatment options, discuss with your gastroenterologist whether an IL-23 inhibitor like guselkumab could be appropriate, and ask about the evidence, administration routes (SC vs IV), dosing, safety, insurance coverage, and access support.
This article is a news report of an FDA approval and summarizes company and investigator statements plus high-level Phase 3 trial references. It does not include detailed efficacy or safety data, head-to-head trial methodology, or prescribing information beyond the dosing schedule mentioned.
Talk with a clinician for individualized interpretation and to review full prescribing and trial information.
